Welcome to our dedicated page for JNCE news (Ticker: JNCE), a resource for investors and traders seeking the latest updates and insights on JNCE stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect JNCE's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of JNCE's position in the market.
Jounce Therapeutics (NASDAQ: JNCE) announced participation in several upcoming investor conferences. Key events include the Cowen & Co. 41st Annual Health Care Conference on March 1, 2021, at 10:30 a.m. ET, and the 42nd Annual Raymond James Institutional Investors Conference on March 2, 2021, at 3:50 p.m. ET. Additional presentations will be available at the H.C. Wainwright Global Life Sciences Conference starting March 9, 2021, and the 33rd Annual ROTH Conference on March 15, 2021. Webcasts will be accessible on Jounce's website for 30 days following the presentations.
Jounce Therapeutics (NASDAQ: JNCE) will announce its fourth quarter and full year 2020 financial results on February 25, 2021, before market open. The management team will host a conference call at 8:00 a.m. ET. Jounce focuses on developing innovative cancer immunotherapies, with key programs like JTX-8064 and vopratelimab in clinical trials. The company aims to transform cancer treatment through a biomarker-driven approach while advancing various development-stage programs and early-stage assets.
Jounce Therapeutics (NASDAQ: JNCE) announced the appointment of Dr. Luisa Salter-Cid to its board of directors on February 12, 2021. With over 20 years in the healthcare field, particularly in immunology and immuno-oncology, her expertise is expected to enhance Jounce's strategic leadership. Dr. Salter-Cid previously served as chief scientific officer at Gossamer Bio and held roles at Bristol Myers Squibb, contributing to over 20 compounds entering clinical development. Her insights are anticipated to support Jounce’s ongoing clinical programs and innovations, particularly for its lead candidate, JTX-8064.
Jounce Therapeutics (NASDAQ: JNCE) announced the initiation of patient enrollment in the INNATE Phase 1 study for JTX-8064, a novel macrophage-targeting therapy. This study will explore JTX-8064 as a monotherapy and in combination with PD-1 inhibitors for patients with advanced solid tumors. Key cohorts will include patients with resistant and sensitive PD-(L)1 tumors. The trial aims to demonstrate proof of concept and assess pharmacodynamics and predictive biomarkers. JTX-8064 is designed to enhance anti-tumor immunity by reprogramming immune-suppressive macrophages.
Jounce Therapeutics (NASDAQ: JNCE) announces its participation in two upcoming investor conferences. A webcast presentation at the H.C. Wainwright BioConnect 2021 Conference will be available on demand starting January 11, 2021, at 6:00 a.m. ET. Additionally, Jounce will present live at the 39th Annual J.P. Morgan Healthcare Conference on January 14, 2021, at 8:20 a.m. ET. Both presentations can be accessed via the Investors and Media section of Jounce's website, with archives available for 30 days. Jounce focuses on developing novel cancer immunotherapies.
Jounce Therapeutics (NASDAQ: JNCE) has been added to the NASDAQ Biotechnology Index, effective December 21, 2020. This index tracks biotechnology and pharmaceutical securities that meet specific eligibility requirements. Jounce focuses on developing cancer immunotherapies and biomarkers, with several ongoing clinical trials, including the SELECT Phase 2 trial for its lead product candidate, vopratelimab. The company has also licensed rights to JTX-1811 to Gilead Sciences. This addition may enhance investor visibility and potential ETF inclusions for JNCE.
Jounce Therapeutics (NASDAQ: JNCE) announced its participation in the Piper Sandler 32nd Annual Virtual Healthcare Conference. CEO Richard Murray, Ph.D., and CMO Elizabeth Trehu, M.D., will engage in a pre-recorded fireside chat available on Jounce's website starting December 1, 2020, at 8:00 a.m. ET. The company focuses on developing cancer immunotherapies, with multiple ongoing programs, including the SELECT Phase 2 trial for its lead candidate, vopratelimab. For more details, visit www.jouncetx.com.
Jounce Therapeutics (NASDAQ: JNCE) announced the FDA's approval to initiate a Phase 1 trial called INNATE for JTX-8064, an anti-LILRB2 antibody, aimed at enhancing anti-tumor immunity. The trial will evaluate JTX-8064 as both a monotherapy and in combination with the PD-1 inhibitor JTX-4014. Enrollment is expected to begin by year-end 2020. This trial targets various tumor types, including those resistant to PD-(L)1 inhibitors, marking a significant step in Jounce's strategy to address unmet needs in cancer treatment.
Jounce Therapeutics, Inc. (NASDAQ: JNCE) presented new preclinical data on JTX-8064, their tumor-associated macrophage program, at the 2020 SITC Annual Meeting. The data suggests that JTX-8064 could identify patients who may respond to the treatment, either alone or in combination with PD-1 inhibitors. Jounce plans to begin enrollment in a Phase 1 trial by year-end 2020, exploring biomarkers that could guide clinical decisions. The study shows promising responses in tumors resistant to PD-1 inhibitors, supporting further development of this novel immunotherapy.
Jounce Therapeutics, Inc. (NASDAQ: JNCE) announced participation in a fireside chat at the Cowen 2020 IO Next Summit on November 13, 2020, at 12:15 p.m. ET. A live webcast of the session will be available on the company's website, with a replay archived for 30 days. Jounce focuses on developing novel cancer immunotherapies, including its lead candidate, vopratelimab, currently in the SELECT Phase 2 trial. The company is also advancing JTX-4014 and JTX-8064, and has licensed JTX-1811 to Gilead Sciences. For details, visit www.jouncetx.com.
